Other research analysts have also recently issued research reports about the company. Wells Fargo & Co. set a $44.00 target price on Mylan and gave the company a hold rating in a research note on Sunday, September 4th. Morgan Stanley restated a hold rating on shares of Mylan in a research note on Tuesday, July 12th. BTIG Research restated a buy rating and issued a $60.00 target price on shares of Mylan in a research note on Tuesday, August 30th. Zacks Investment Research cut Mylan from a buy rating to a hold rating in a research note on Friday, August 5th. Finally, Royal Bank Of Canada lowered their target price on Mylan from $52.00 to $48.00 and set a sector perform rating for the company in a research note on Tuesday, September 6th. Ten investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of Buy and an average target price of $54.76.
Mylan (NASDAQ:MYL) opened at 41.31 on Thursday. Mylan has a 1-year low of $37.59 and a 1-year high of $55.51. The company has a 50 day moving average of $43.78 and a 200 day moving average of $44.62. The company has a market capitalization of $22.10 billion, a PE ratio of 26.15 and a beta of 1.25.
Mylan (NASDAQ:MYL) last issued its quarterly earnings data on Tuesday, August 9th. The company reported $1.16 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.13 by $0.03. The firm had revenue of $2.56 billion for the quarter, compared to analyst estimates of $2.58 billion. Mylan had a return on equity of 23.22% and a net margin of 8.11%. The business’s quarterly revenue was up 8.0% compared to the same quarter last year. During the same period last year, the company earned $0.91 EPS. On average, analysts predict that Mylan will post $4.96 earnings per share for the current fiscal year.
In other Mylan news, CEO Heather M. Bresch sold 100,200 shares of the business’s stock in a transaction dated Tuesday, August 9th. The stock was sold at an average price of $50.00, for a total transaction of $5,010,000.00. Following the completion of the sale, the chief executive officer now owns 828,318 shares of the company’s stock, valued at $41,415,900. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.71% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the stock. Advisory Services Network LLC increased its position in shares of Mylan by 43.6% in the second quarter. Advisory Services Network LLC now owns 2,537 shares of the company’s stock valued at $110,000 after buying an additional 770 shares during the last quarter. Checchi Capital Advisers LLC increased its position in shares of Mylan by 6.6% in the second quarter. Checchi Capital Advisers LLC now owns 2,637 shares of the company’s stock valued at $114,000 after buying an additional 164 shares during the last quarter. Integrated Investment Consultants LLC acquired a new position in shares of Mylan during the second quarter valued at approximately $145,000. Tower Research Capital LLC TRC increased its position in shares of Mylan by 100.4% in the second quarter. Tower Research Capital LLC TRC now owns 4,182 shares of the company’s stock valued at $181,000 after buying an additional 2,095 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. increased its position in shares of Mylan by 48.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 4,235 shares of the company’s stock valued at $184,000 after buying an additional 1,388 shares during the last quarter. 60.20% of the stock is owned by institutional investors and hedge funds.
Mylan Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan Inc. and related companies with MarketBeat.com's FREE daily email newsletter.